- Home
- SGN vs PALI Comparison
SGN vs PALI Comparison
Compare SGN & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- PALI
- Stock Information
- Founded
- SGN 2019
- PALI 1996
- Country
- SGN United States
- PALI United States
- Employees
- SGN N/A
- PALI N/A
- Industry
- SGN
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGN
- PALI Health Care
- Exchange
- SGN Nasdaq
- PALI Nasdaq
- Market Cap
- SGN 4.1M
- PALI 3.5M
- IPO Year
- SGN 2023
- PALI N/A
- Fundamental
- Price
- SGN $3.11
- PALI $1.75
- Analyst Decision
- SGN
- PALI Strong Buy
- Analyst Count
- SGN 0
- PALI 2
- Target Price
- SGN N/A
- PALI $23.00
- AVG Volume (30 Days)
- SGN 79.0K
- PALI 3.7M
- Earning Date
- SGN 12-24-2024
- PALI 11-12-2024
- Dividend Yield
- SGN N/A
- PALI N/A
- EPS Growth
- SGN N/A
- PALI N/A
- EPS
- SGN N/A
- PALI N/A
- Revenue
- SGN $576,488.00
- PALI N/A
- Revenue This Year
- SGN N/A
- PALI N/A
- Revenue Next Year
- SGN N/A
- PALI N/A
- P/E Ratio
- SGN N/A
- PALI N/A
- Revenue Growth
- SGN 147.76
- PALI N/A
- 52 Week Low
- SGN $2.80
- PALI $1.38
- 52 Week High
- SGN $73.44
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- SGN 31.18
- PALI 40.97
- Support Level
- SGN $2.80
- PALI $1.59
- Resistance Level
- SGN $3.59
- PALI $2.20
- Average True Range (ATR)
- SGN 0.84
- PALI 0.39
- MACD
- SGN -0.08
- PALI 0.02
- Stochastic Oscillator
- SGN 5.34
- PALI 19.27
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.